The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Open accessAbstract
Key Points: A risk-adapted, MRD-driven transplant strategy is a feasible approach for the treatment of younger adults with AML. Pretransplant MRD positivity should not contraindicate delivery of an allogeneic stem cell transplant.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350 · cited 2×
“NCCN-IR MRD pos 35(0) 29(5) 29(5) 29(5) 29(5)”
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia
Metzeler, K. H., Herold, T., Rothenberg-Thurley, M., Amler, S., Sauerland, M. C., Görlich, D., Schneider, S., Konstandin, N. P., Dufour, A., Bräundl, K., et al. (2016) · Blood · doi:10.1182/blood-2016-01-693879 · Cited by 529
Cited by
Döhner, H., Wei, A. H., Appelbaum, F. R., Craddock, C., DiNardo, C. D., Dombret, H., Ebert, B. L., Fenaux, P., Godley, L. A., Hasserjian, R. P., et al. (2022) · Blood · doi:10.1182/blood.2022016867 · Cited by 3,279
Heuser, M., Freeman, S. D., Ossenkoppele, G. J., Buccisano, F., Hourigan, C. S., Ngai, L. L., Tettero, J. M., Bachas, C., Baer, C., Béné, M.-C., et al. (2021) · Blood · doi:10.1182/blood.2021013626 · Cited by 763
Self-citationCirculating tumor DNA and liquid biopsy in oncology
Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020) · Nature Cancer · doi:10.1038/s43018-020-0043-5 · Cited by 600
Yu, S., Lin, T., Nie, D., Zhang, Y., Sun, Z., Zhang, Q., Wang, C., Xiong, M., Fan, Z., Huang, F., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00591-4 · Cited by 23
“But when is the best timepoint making decisions on PRT is still inconclusive [19, 20, 23, 24].”
Background
Metadata
- Authors
- Venditti, A., Piciocchi, A., Candoni, A., Melillo, L., Calafiore, V., Cairoli, R., de Fabritiis, P., Storti, G., Salutari, P., Lanza, F., Martinelli, G., Luppi, M., Mazza, P., Martelli, M. P., Cuneo, A., Albano, F., Fabbiano, F., Tafuri, A., Chierichini, A., Tieghi, A., Fracchiolla, N. S., Capelli, D., Foà, R., Alati, C., La Sala, E., Fazi, P., Vignetti, M., Maurillo, L., Buccisano, F., Del Principe, M. I., Irno-Consalvo, M., Ottone, T., Lavorgna, S., Voso, M. T., Lo-Coco, F., Arcese, W., & Amadori, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2019-08-08
- Volume
- 134
- Issue
- 12
- Pages
- 935-945
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2968344249
- Cited by
- 220
- References
- 2
- FWCI
- 15.71
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood.2018886960
- The paper
- Venditti, A., Piciocchi, A., Candoni, A., Melillo, L., Calafiore, V., Cairoli, R., de Fabritiis, P., Storti, G., Salutari, P., Lanza, F., Martinelli, G., Luppi, M., Mazza, P., Martelli, M. P., Cuneo, A., Albano, F., Fabbiano, F., Tafuri, A., Chierichini, A., . . . Amadori, S. (2019). GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. https://doi.org/10.1182/blood.2018886960
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.